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Diameter of abdominal aortic aneurysm and
outcome of endovascular aneurysm repair:
Does size matter? A report from EUROSTAR
Noud Peppelenbosch, MD,a Jacob Buth, MD, PhD,a Peter L. Harris, MD, FRCS,b Corine van
Marrewijk, MSc,a and Gerdine Fransen, MSc,a for the EUROSTAR Collaborators Eindhoven,
The Netherlands; and Liverpool, England
Objectives: This study was undertaken to determine the effect of the preoperative diameter of abdominal aortic aneurysms
on the midterm outcome after endovascular abdominal aneurysm repair (EVAR).
Method: The data for 4392 patients who had undergone EVAR were analyzed. Patients were enrolled over 6 years to June
2002 in the EUROSTAR database. Outcomes were compared between three groups defined by the preoperative diameter
of the aneurysm: group A (n  1962), 4.0 to 5.4 cm; group B (n  1528), 5.5 to 6.4 cm; and group C (n  902), 6.5
cm or larger. Patient characteristics, details of aortoiliac anatomy, operative procedures, old or current device generation,
and postoperative complications in the three patient groups were compared. Outcome events included aneurysm-related
death, unrelated death, conversion, and post-EVAR rupture of the aneurysm. Life table analysis and log-rank tests were
used to compare outcome in the three study groups. Multivariate Cox models were used to determine whether baseline
and follow-up variables were independently associated with adverse outcome events.
Results: Patients in group C were significantly older than patients in groups A and B (73 years vs 70 and 72 years,
respectively; P  .003 – P < .0001 for different group comparisons), and more frequently were at higher operative risk
(American Society of Anesthesiologists classification >3; 63% vs 48% and 54%; P  .0002–P <.0001). Device-related
(type I) endoleaks were more frequently observed at early postoperative arteriography in group C compared with groups
A and B (9.9% vs 3.7% and 6.8%; P  .01–P < .0001). Postoperatively systemic complications were more frequently
present in group C (17.4% vs 12.0% in group A and 12.6% in group B; P < .0001 and .001). The first-month mortality
was approximately twice as high in group C compared with the other groups combined (4.1% vs 2.1%; P < .0001). Late
rupture was most frequent in group C. Follow-up results at midterm were less favorable in groups C and B compared with
group A (freedom from rupture, 90%, 98%, and 98% at 4 years in groups C, B, and A, respectively; P < .0001 for group
C vs groups A and B). Aneurysm-related death was highest in group C (88% freedom at 4 years, compared with 95% in
group B and 97% in A; P  .001 and P < .0001, respectively; group B vs A, P  .004). The annual rate of
aneurysm-related death in group C was 1% in the first 3 years, but accelerated to 8.0% in the fourth year. Incidence of
unrelated death also was higher in groups C and B than in group A (76% and 82% freedom at 4 years vs 87%; P < .0001
for both comparisons). Ratio of aneurysm-related to unrelated death was 23%, 21%, and 50% in groups A, B, and C,
respectively. Cox models demonstrated that the correlation between large aneurysms (group C) and all assessed outcome
events was independent and highly significant. Older generation devices had an independent association with aneurysm-
related and unrelated deaths (P  .02 and P  .04, respectively). However, this correlation was less strong than large
aneurysm diameter (P  .0001 and P  .0009, respectively).
Conclusions: The midterm outcome of large aneurysms after EVAR was associated with increased rates of aneurysm-
related death, unrelated death, and rupture. Reports of EVAR should stratify their outcomes according to the diameter
of the aneurysm. Large aneurysms need a more rigorous post-EVAR surveillance schedule than do smaller aneurysms. In
small aneurysms EVAR was associated with excellent outcome. This finding may justify reappraisal of currently accepted
management strategies. (J Vasc Surg 2004;39:288-97.)
Endovascular aneurysm repair (EVAR) has gained an
increasingly important role in clinical management of ab-
dominal aortic aneurysms since its introduction in the early
1990s. The availability of EVAR may change hitherto
accepted surgical decision-making for abdominal aortic
aneurysm (AAA) repair. In conventional surgical AAA re-
pair the risks of the procedure are considerable, and must be
considered against the benefits of preventing death from
rupture. Similarly, differences in early and late outcome
after EVAR must be balanced against the natural history of
untreated AAA. Since the publication by Szilagyi et al,1 size
of the aneurysm has been recognized as the predominant
risk factor for death from rupture, with low risk associated
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with small aneurysms, intermediate risk with medium-sized
aneurysms, and dramatically increased risk with large aneu-
rysms.1-6 The definition of a small aneurysm has changed
somewhat after recently published results of two trials that
compared the outcome of an initially conservative approach
with primary open repair.7,8 The threshold diameter for a
small aneurysm in both trials was 5.5 cm, as measured on
the largest section of the aneurysm. Randomized compar-
ative studies for aneurysms with diameter larger than 5.5
cm are generally considered unethical, on the basis of
indirect but compelling evidence of high risk for rupture
from natural history studies in patients unfit for open repair
or refusing treatment.5,6,9,10
A large number of cohort studies of open AAA repair,
published over two decades, have identified several patient-
related variables that determine either excellent or less
optimal operative or long-term outcomes of treatment,
with age, female gender, comorbid conditions, and re-
quired level of aortic clamping the most frequently cited
risk factors.11-13 However, almost all series on open AAA
repair have neglected to assess the achieved modification of
the risk for rupture according to patient cohorts stratified
according to aneurysm size. In contrast, in a previous
publication on the EUROSTAR collaborative series on
patients unfit for open repair undergoing EVAR, a positive
correlation was observed between comorbidity-related and
aneurysm-related death, and larger aneurysm size.14 Mean-
while, a few other studies on outcome of EVAR have
demonstrated this correlation of aneurysm size with mid-
term outcome after treatment as well.15-17 The objective of
the present study was to assess the influence of aneurysm
size on the early and late outcome of EVAR in the entire
prospectively enrolled series of patients in the EUROSTAR
database.
METHOD
Data for 4392 patients operated on over 6 years, ending
in June 2002, who were enrolled prospectively in the
EUROSTAR database constituted the basis of this analysis.
An account of the organization of the EUROSTAR Regis-
try and reports on various aspects after EVAR have been
published.18-20 For all patients, minimal follow-up was 1
month. Patients with an aneurysm smaller than 4.0 cm in
diameter, including those with large iliac aneurysms, had
been excluded from the study cohort. This cohort repre-
sents patients from 110 European institutions (Appendix 1,
online only). All patients received commercially available,
CE-approved devices, including AneuRx, EVT/Ancure,
Excluder, Stentor, Talent, Vanguard, Zenith, and “other.”
Four thousand fifty (92.2%) patients received an endograft
of bifurcated configuration, 193 (4.4%) patients received an
aortouniiliac endograft, and 149 (3.4%) patients received a
straight tube endograft. To assess the influence of size on
the early and midterm outcome after EVAR the study
cohort was subdivided according to preoperative aneurysm
diameter: group A, 4.0 to 5.4 cm; group B, 5.5 to 6.4 cm;
and group C greater than 6.5 cm.
Inclusion criteria, as defined in the Registry protocol,
comprised elective treatment for AAA and vascular anat-
omy suitable for implantation of a stent graft. Baseline data
including comorbidity, estimate of unfitness for open re-
pair,14 anatomic aspects, and operative details were re-
corded by the participating institutions on case record
forms and were submitted for inclusion to the Data Regis-
try Center. Findings at follow-up visits, which involved
clinical examination, computed tomography (CT), or (in
5% of visits) angiography, magnetic resonance imaging, or
ultrasound studies, were recorded on data forms and were
returned at regular intervals to the Data Registry Center for
processing and analysis. There was no outside monitoring
of the centers or involvement of a core laboratory for the
evaluation of CT or other imaging studies. Follow-up visits,
according to the protocol, were scheduled at 1, 6, 12, 18,
and 24 months, and annually thereafter. Reminders for
overdue follow-up data were regularly sent to the institu-
tions participating in the project. Outcome reporting ad-
hered to the guidelines outlined by the Ad Hoc Committee
for Standardized Reporting Practices in Vascular Surgery of
The Society for Vascular Surgery/American Association for
Vascular Surgery.21 Deaths that occurred within 30 days of
the initial procedure were categorized as operative deaths,
and late deaths as those that occurred after 30 days. Deaths
were also classified as aneurysm-related or unrelated. Aneu-
rysm-related deaths included operative deaths and deaths
that occurred as a result of aneurysm rupture, endograft
infection, or within 1 month after a secondary surgical
procedure to treat late complications of the aneurysm.
Other outcome events observed during follow-up in-
cluded endoleaks, device migration, severe device kinking,
occlusion, and aneurysm growth. Only endoleaks that were
identified at 1 month and thereafter were included in the
analysis; endoleaks at completion angiography were not
considered. Endoleaks were classified as follows: type I, or
endoleaks originating from the attachment site at the prox-
imal infrarenal aortic neck or from the distal extremity of
the endograft at the level of the iliac arteries; type II, or
reperfusion endoleaks from the inferior mesenteric, lum-
bar, accessory renal, sacral, and hypogastric arteries; and
type III, or endoleaks from the endograft itself, either from
fabric damage or from connection sites between different
device components. In cases in which different types of
endoleaks were observed at different follow-up periods,
types I and III were considered above type II for the
analysis. The interval between the date of surgery and the
date on which an endoleak was identified for the first time
was used for life-table analysis.
Aneurysm growth was determined on the recording of
an increase in aneurysm diameter measured at its largest
section, from outer wall to outer wall across the minor
diameter on the axial CT section. Aneurysm enlargement
was defined as a diameter increase of at least 8 mm relative
to the preoperative measurements on CT scans. The max-
imum recorded aneurysm diameter during follow-up was
used for this analysis, and any subsequent smaller diameter
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that may have occurred because of secondary treatment was
omitted.
Results were reported as mean, range, and percentage
of patients with discrete variables, unless otherwise speci-
fied. Preoperative patient characteristics, comorbid condi-
tions, aneurysm anatomy at the initial procedure, and de-
tails regarding the procedure and devices were correlated
with the defined study groups with univariate analysis.
Differences in findings between study groups were assessed
with 2 tests for discrete variables and with Mann-Whitney
tests for continuous variables. All variables, including size
classification, with a significant correlation with an adverse
outcome event were entered in a multivariate Cox analysis
to assess independent associations. A dichotomous catego-
rization of used device brands was defined, with Stentor
and Vanguard in one category and any other endograft in
the other. This variable “device category” was entered in
the model irrespective whether a significant correlation
with the outcome event was found at univariate analysis. P
 .05 was considered to represent a significant difference.
Cumulative rates of freedom from aneurysm-related
deaths, unrelated deaths, aneurysm rupture, conversion to
Table I. Demographic characteristics, comorbidity, and details of aortoiliac anatomy in 4392 patients
Aneurysm diameter
Group A
4.0-5.4 cm
(1962 patients)
Group B
5.5-6.4 cm
(1528 patients)
Group C
 6.5 cm
(902 patients) P
n % n % n %
Group A vs
group B
Group B vs
group C
Group A vs
group C
Patient age (y)
Mean 69.7 72.1 73.3 .0001 .0093 .0001
Range 43-94 49-109 50-93
Male gender 1822 93 1416 93 857 95 NS .02 .03
ASA class 3 944 48 831 54 565 63 .0002 .0001 .0001
History of cardiac symptoms
or interventions
1040 56 899 62 588 68 .002 .002 .0001
Renal insufficiency 304 17 265 18 193 23 NS .01 .0001
Pulmonary symptoms 673 37 619 43 400 47 .0003 .06 .0001
Diameter of infrarenal
aortic neck (mm)
Mean 22.7 23.3 23.9 .0001 .0001 .0001*
Range 12-40 13-38 10-40
Significant angulation
Infrarenal neck 268 14 392 26 334 37 .0001 .0001 .0001
Aneurysm 164 8 183 12 137 15 .0004 .02 .0001
Iliac arteries 741 38 704 46 452 50 .0001 .05 .0001
Aneurysmatic common
iliac arteries
276 15 271 19 184 23 .003 .0006 .0001
Missing data on comorbidity figures ranged from 220 to 318 per item; in aneurysmatic common iliac arteries, 374 missing data.
Table II. Devices used in 4392 patients
No. of devices
Group A
4.0-5.4 cm
(1962 patients)
Group B
5.5-6.4 cm
(1528 patients)
Group C
6.5 cm
(902 patients)
n % n % n %
AneuRx 877 438 50* 296 34 143 16
EVT/Ancure 150 62 41 56 37 32 21
Excluder 341 158 46 129 38 54 16
Stentor 282 142 50 93 33 47 17
Talent 821 307 37 322 39 192 23†
Vanguard 905 438 48‡ 295 33 172 19
Zenith 891 344 37 300 34 247 28§
Other 108 62 57 31 29 15 14
Unknown 17 11 6
Only more frequent use of brand in device groups A and C is indicated.
*P  .0002 more frequent use in group A.
†P  .0001 more frequent use in group C.
‡P  .04 more frequent use in group A.
§P  .0001 more frequent use in group C.
P  .004 more frequent use in group A.
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open repair, and various types of endoleaks were assessed
with life-table analysis. Only rates with less than 10% SE are
indicated in the Results and in the figures. Significant
differences between study groups were assessed with log-
rank testing. All statistical analyses were performed with
SAS Statistical Software (version 1.12; SAS Institute, Cary,
NC).
RESULTS
The 4392 patients, 4095 men and 297 women, ranged
in age from 42 to 100 years. Average diameter of the
aneurysm sac was 57.2 cm (range, 4.0-14.5 cm) in minor
dimension. Group A included 1962 patients with aneurysm
diameter 4.0 to 5.4 cm, group B included 1528 patients
with aneurysm diameter 5.5 to 6.4 cm, and group C
included 902 patients with aneurysm diameter greater than
6.4 cm. Patients in group C were on average 1.2 to 3.6
years older than those in groups A and B, more frequently
had American Society of Anesthesiologists (ASA) class 3 or
4 disease, and more frequently had cardiac, renal, and
pulmonary comorbidity, compared with the other groups
(Table I). Regarding existing anatomy, patients in group C
had a higher incidence of significant angulation in the neck,
the aneurysm, and the iliac arteries, and on average a 0.6 to
1.2 mm wider infrarenal neck. In addition, aneurysm dila-
tation of the common iliac arteries was more frequently
observed in group C than in the other groups (Table I).
Operative time was 157 minutes in group C, compared
with 140 minutes in group A and 132 minutes in group B
(P  .0001). Talent and Zenith endografts were signifi-
cantly more frequently used in group C (Table II). Other
operative aspects more frequently observed in group C
included use of additional procedures (37% vs 31% in group
B and 30% in group A; P  .0007) and a higher incidence
of type I endoleak at completion angiography (9.9% vs 6.8%
in group B and 3.7% in group A; group A vs group B, P 
.001; group A vs group C, P .0001; group B vs group C,
P .01). Primary or first-month conversion to open repair
was performed in 1.1% of patients (n  21) in group A,
1.4% of patients (n  22) in group B, and 2.3% of patients
(n 21) in group C (group A vs group C, P .009; other
group comparisons, not significant [NS]).
The overall first-month mortality was 2.5% (108 pa-
tients). Mortality was 4.1% in group C, compared to 2.1%
in groups A and B combined (P  .0001; 2.6% in group B
and 1.6% in group A). The first-month mortality in the
Stentor and Vanguard category was 3.0%, and in other
endografts was 2.2% (NS).
Cardiac complications occurred in 5.6% of patients in
group C, 3.3%, in group B, and 2.8% in group (group A vs
group C, P  .003; group B vs group C, P  .008; group
A vs group B, NS). Pulmonary complications occurred in
3.0% of patients in group C, 2.0% in group B, and 1.6% in
group A (group A vs group C, P .01; other comparisons,
NS). First-month systemic complications combined were
observed in 17.4% of patients in group C, 12.6% of patients
in group B, and 12.0% of patients in group A (group A vs
group C, P .0001; group B vs group C, P .001; group
A vs group B, NS). There was no difference in early proce-
dure-related or device-related complications (3.3%, 2.8%,
and 2.9% in groups C, B, and A, respectively). Hospital stay
was longer in groups C and B (7.0, 6.1, and 5.5 days in
groups C, B, and A, respectively (group A vs group B, P 
.004; group A vs group C, P  .0001; group B vs group
C, P  .001).
Mean duration of follow-up was 18.4 months (range,
1-72 months), with 20.9 months (range, 1-96) in group A,
17.4 months (1-84 months) in group B, and 14.5 months
(1-84 months) in group C. The difference in follow-up
duration was significant (P .0001 for any group compar-
ison). The percentage of patients lost to follow-up after 2
years was 52% in group A, 55% in group B, and 62 in group
C (NS). Patient survival was 76.0% at 5 years. Group C had
significantly lower survival compared with groups B and A
(62.0%, 69.6%, and 84.2%, respectively, at 5 years; group A
vs group B, P  .0001; group B vs group C, P  .0001;
group A vs group C, P  .0001).
Aneurysm-related deaths. The freedom from aneu-
rysm-related death in the entire study cohort was 93.9% at
5 years. Aneurysm-related deaths occurred in 53 patients in
group C, 52 patients in group B, and 39 patients in group
A, for a freedom from aneurysm-related death at 5 years of
87.9%, 95.0%, and 97.0% in the three groups, respectively
(group A vs group B, P  .004; group A vs group C, P 
.0001; group B vs group C, P  .001; Fig 1; numbers of
patients in Appendix 2, online only). Most aneurysm-
related deaths in groups B and C during follow-up occurred
in the fourth year. In group C the aneurysm-related death
rate was 1% annually in the first 3 years (operative deaths
not included) and 8% in the fourth year. In group B the
aneurysm-related annual death rate was 0.3% in the first 3
years and 2.1% in the fourth and fifth years. This pattern can
be described as a gradual increase in the first 3 years,
followed by an accelerated increase in aneurysm-related
deaths in the fourth year in groups B and C (Fig 1). This
trend was not apparent in group A.
Fig 1. Cumulative freedom from aneurysm-related death. Note
low attrition of survival in first 3 years of follow-up and rapid
attrition in fourth year. Gp, Group.
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Freedom from aneurysm-related deaths at 3 years strat-
ified by device category was 95.2% in patients with Stentor
and Vanguard devices and 96.9% in patients with other
endografts (P  .01). Multivariate analysis indicated that
large aneurysm (group C), patient age, renal insufficiency,
pulmonary comorbidity, unfitness for open repair, and use
of Stentor and Vanguard devices as factors with an inde-
pendent correlation with increased risk for aneurysm-re-
lated death (Table III). The level of significance was less for
the device category (P  0.02) than for size group C (P 
.0001). A multivariate model of variables observed at fol-
low-up, with aneurysm-related deaths omitting the first-
month deaths (ie, “late” aneurysm-related death) as
outcome event indicated an independent significant corre-
lation with large aneurysms (group C), proximal endoleak
(type I), kinking of the device, and aneurysm expansion
during follow-up (Table III). In this Cox model there was
no correlation with use of Stentor and Vanguard device.
Aneurysm-related complications. Rupture post-
EVAR occurred in 32 patients in the entire study cohort,
with 16 ruptures in group C, 9 ruptures in group B, and 7
ruptures in group A. Freedom from rupture after 4 years
was observed in 97.2% of the entire group, 90.5% in group
C, 98.3% in group B, and 98.3% in group A (group A vs
group B, P  .13; group A vs group C, P  .0001; group
B vs group C, P  .0001; Fig 2; numbers of patients in
Appendix 2, online only). The rate of rupture during the
study period per patient-year was 0.005 in the entire co-
hort, 0.015 in group C, 0.004 in group B, and 0.002 in
group A. Ruptures occurred in patients who had received
an AneuRx (3 of 877), Excluder (1 of 341), Stentor (6 of
282), Talent (5 of 821), Vanguard (15 of 905), Zenith (1
of 891) and “other” (1 of 108) devices. No single device
brand was significantly associated with a higher risk for
post-EVAR rupture. The dichotomized variable of used
endograft at univariate analysis was not associated with a
significantly increased risk for rupture. The 3-year rate of
freedom from rupture was 98.5% with Stentor and Van-
guard and 99.2% with other device brands. Variables ob-
served at follow-up that were independently associated with
a higher risk for rupture included large aneurysms (group
C), midgraft endoleak type III, and aneurysm expansion
during follow-up (Table IV). In this Cox model the use of
the Stentor or Vanguard device did not significantly corre-
late with rupture.
Type I proximal endoleak had a higher incidence in
group C (89.5% freedom from endoleak at 4 years) com-
pared with group A (94.7%; P .002) and group B (95.1%;
P  .002). Type I distal endoleak also had a higher inci-
dence in group C (84.9% freedom from endoleak at 4 years)
compared with group A (88.7%; P .0004). There was no
significant difference between groups C and B, and groups
A and B. The incidence of type III endoleaks was not
significantly different in the three size groups (freedom
from endoleak at 4 years, 90.3%, 87.7%, and 85.6% for
groups C, B, and A, respectively). Similarly, the incidence
of type II endoleaks, migration, kinking, and limb stenosis
or thrombosis was comparable in the three groups.
Late conversion to open repair (after the first postop-
erative month) had a higher incidence in group C (86.2%
Table IV. Risk factors for rupture of aneurysm, outcome
of multivariate analysis
Follow-up variables
Hazard
ratio
95% Confidence
interval
Aneurysm size, group C 7.7 3.1-18.7
Type III endoleak 3.8 1.7-8.3
Aneurysm growth 4.1 1.4-12.1
Table V. Risk factors for conversion to open repair,
outcome of multivariate analysis
Follow-up variables
Hazard
ratio
95% Confidence
interval
Aneurysm size, group C 1.6 1.1-2.3
Type I proximal endoleak 4.0 2.7-5.8
Type II endoleak 2.0 1.4-2.9
Type III endoleak 1.7 1.2-2.5
Migration 1.7 1.1-2.5
Occlusion of limb 6.4 4.6-9.0
Aneurysm growth 3.9 2.4-6.4
Table VI. Risk factors for death not related to aneurysm,
outcome of multivariate analysis
Baseline variables
Hazard
ratio
95% Confidence
interval
Aneurysm size, group C 1.5 1.1-2.1
Aneurysm size, group B 1.5 1.1-1.9
Age of patient 1.0 1.0-1.1
Renal insufficiency 1.4 1.1-1.9
Pulmonary condition 1.6 1.3-2.1
Unfit for open aneurysm repair 1.8 1.4-2.4
Stentor or Vanguard device 1.3 1.0-1.7
Table III. Risk factors for aneurysm-related death,
outcome of multivariate analysis
Variable
Hazard
ratio
95% Confidence
interval
Baseline variables (early and late aneurysm-related death)
Aneurysm size, group C 2.5 1.6-4.0
Age 1.1 1.04-1.09
Renal insufficiency 1.8 1.2-2.7
Pulmonary condition 1.7 1.1-2.4
Unfit for open aneurysm repair 1.7 1.1-2.4
Stentor or Vanguard device 1.5 1.1-2.3
Follow-up variables (only late aneurysm-related death)
Aneurysm size, group C 6.0 2.6-14.1
Type I proximal endoleak 3.5 1.4-9.0
Kinking of device 3.5 1.5-8.3
Aneurysm growth 10.5 4.8-23.0
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freedom from conversion at 4 years) compared with group
A (93.4%; P  .003) and group B (93.2%; P  .01).
Variables observed during follow-up with an independent
correlation with the decision to open conversion included
large aneurysm (group C), proximal endoleak (type I),
mid-graft endoleak (type III), type II endoleak, device
migration, limb occlusion, and aneurysm expansion (Table
V). Correlation of the device category Stentor or Vanguard
and conversion did not achieve significance (P .05). The
incidence of aneurysm growth was not significantly differ-
ent in groups C, B, and A (Fig 3; numbers of patients in
Appendix 2, online only).
Unrelated deaths. Freedom from aneurysm- unre-
lated death in the entire study cohort was 81.0% at 5 years
of follow-up. Cumulative death rates due to comorbidity
were significantly lower in groups B and C compared with
group A (freedom from unrelated death at 4 years, 75.6% in
group C, 82.3% in group B, 86.9% in group A; Fig 4;
numbers of patients in Appendix 2, online only). There was
no statistical difference between unrelated deaths between
groups C and B. In contrast with aneurysm-related deaths,
there was a progressive attrition of freedom from unrelated
deaths over the first 5 years of follow-up (5.8% and 4.8%
annually in groups C and B; Fig 4). Of factors recorded at
baseline, aneurysm size groups B and C, patient age, pres-
ence of renal dysfunction, adverse pulmonary condition,
and subjective assessment of unfitness for open repair by the
managing physicians had a significant independent correla-
tion with the risk for death unrelated to aneurysm or
treatment (Table VI). The use of the Stentor or Vanguard
device had a borderline significant correlation with unre-
lated death (P  .04), as opposed to a highly significant
correlation of groups C (P  .009) and B (P  .007).
DISCUSSION
Size of an AAA has several implications for manage-
ment with EVAR. First, it was recognized that large-diam-
eter aneurysms were less often suitable for endograft repair
than smaller aneurysms.22-24 Most frequently aortic necks
were either too wide, too short, severely angulated, or these
factors combined, rendering reliable infrarenal endograft
fixation and sealing uncertain. However, with the newer
generation of devices sealing and fixation is achievable in
aneurysms that, on the basis of anatomy, previously would
have been rejected for stent-graft treatment.25-30 This is in
keeping with the findings in the present study of patients
undergoing EVAR. The size of the neck and angulation at
several levels of the aortoiliac segment and aneurysm dila-
tation in iliac arteries demonstrated a significant correlation
with size groups C and B.
The correlation of larger aneurysm with a higher inci-
dence of preoperative comorbidity is appreciable in this
study. Cardiac, renal, and pulmonary conditions and ge-
neric estimates of increased operative risk, such as ASA class
3 and 4 disease and subjective assessment of patients as
Fig 2. Cumulative freedom from rupture after endovascular an-
eurysm repair. Gp, Group.
Fig 3. Cumulative proportion of patients with aneurysm growth
after endovascular aneurysm repair. Gp, Group; NS, not signifi-
cant.
Fig 4. Cumulative freedom from unrelated death. Dashed arrow,
Progressive attrition of survival throughout follow-up period. Gp,
Group.
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unfit, had a higher prevalence in patients in group C. A
correlation of increased operative risk and larger aneurysm
size had been observed previously.14,16,31 Comparison of
operative details in the present assessment demonstrated
unfavorable outcome in large (group C) or medium-sized
(group B) aneurysms in operating time, length of hospital
stay, and increased rate of type I endoleaks at completion
arteriography. These events are typically associated with
more complex anatomy or reflected greater postoperative
morbidity.22,32,33 Moreover, additional procedures were
more frequently required in group C than in the other
groups.
A low perioperative mortality in comparison with con-
ventional surgery as the benchmark has been one of the
assumed assets of EVAR from the beginning of its devel-
opment. A perioperative mortality of 4.1% with large aneu-
rysms is higher than in institutional series and in the
EUROSTAR series as a whole,20,34 but still compares
favorably with the mean procedural mortality of 5.5% re-
ported in a recent review of several studies of open aneu-
rysm surgery.35 However, comparison of perioperative
mortality rates in different series is always a dubious exer-
cise, owing to differences in patient selection and study
design.
When reporting midterm and long-term results after
EVAR, it has been advised that outcome events related to
the aneurysm or treatment be differentiated from events
associated with preexisting comorbid factors, that is, unre-
lated events.36 With regard to death rates during follow-up,
a number of interesting findings came out of the present
analysis. First, we noted a relatively smaller contribution of
aneurysm-related death to the rate of death from all causes
in the entire study cohort (freedom from death at 5 years,
94% vs 76%, respectively). Second, there was a progressive
increase in both aneurysm-related and unrelated death rates
with increasing aneurysm diameter. Third, the ratio of
aneurysm-related to unrelated death rates demonstrated
notable differences between groups, with the contribution
of related deaths being largest in group C (approximately
50%, compared with 28% and 23% at 4 years in groups B
and A, respectively; compare Figs 1 and 4). Thus the
aneurysm-related death rate is largest in group C in an
absolute sense and in a relative sense. In theory, one might
conclude that the potential advantage of the minimally
invasive technique becomes smaller in patients with large
aneurysms, which is in agreement with previous oberva-
tions that EVAR is most durable in patients with small and
medium-sized aneurysms.37 On the other hand, one must
consider that prevention of death from rupture in the vast
majority in the patient category with the most unfavorable
natural history and highest risk for open repair may be the
best indication for EVAR.14
The relatively high rate of aneurysm-related midterm
mortality is linked to high-risk events, such as late conver-
sion and aneurysm rupture. The underlying cause for these
events must be sought in the same unfavorable anatomic
conditions that cause postoperative morbidity. In addition,
a higher frequency of thrombus lining in aneurysm necks
and common iliac arteries, and calcifications in the sealing
zones are causes of less favorable outcome.26,30 Although
these latter characteristics were not recorded as such, be-
cause they are difficult to quantify in a multicenter registry,
their importance must not be underestimated. Adverse
anatomy–related findings including a significantly higher
incidence of type I endoleaks of both the proximal and
distal variety were more frequently observed in large aneu-
rysms. Thus detected and undetected anatomic character-
istics may account for the higher rate of rupture, conver-
sion, and aneurysm-related deaths in patients with large
aneurysms compared with medium-sized and small aneu-
rysms.
Distribution of the various outcome events during
follow-up demonstrated characteristic patterns. Unrelated
deaths occurred with a relatively constant annual failure
rate of 5.8% in group C throughout 5 years of follow-up. In
contrast, aneurysm-related death after the first month
clearly was delayed by 3 years before events occurred with
higher frequency, a phenomenon that was most apparent in
group C. Within the first 3 years the annual failure rate in
group C was 1%, compared with an interval failure of 8% in
the fourth year. If we assume that aneurysm-related death
and rupture are preventable, it may be argued that after 3
years of follow-up intensified imaging surveillance may be
effective for early detection of indicators of procedural
failure, such as aneurysm enlargement, migration, type I or
III endoleaks, device kinking, or device deterioration.
These factors demonstrated an independent correlation in
the multivariate analysis (Table III). Regarding intensified
surveillance, one may consider more frequent follow-up
visits, with precise screening of plain abdominal x-ray films,
volume measurements of the aneurysm sac, and three-
dimensional reconstruction of CT scans.38-40
Although aneurysm diameter was the main variable in
this outcome study, other variables recorded either at base-
line or during follow-up were assessed as potential con-
founders. Several variables were found to have an indepen-
dent association with adverse outcome measures. Recently
an increased incidence of late complications has been attrib-
uted to devices of older generations, presently withdrawn
from the market.41 In our analysis we included this variable,
defined as the use of Stentor or Vanguard endografts, in the
multivariate Cox models. We observed that there was an
independent correlation of old-technology endografts with
aneurysm-related and unrelated deaths. However, this cor-
relation was not so strong as the initial presence of a large
aneurysm (group C) for aneurysm-related death, and me-
dium-sized and large AAA (groups B and C) for unrelated
death.
Of surprise, enlargement of the aneurysm, although
correlating with rupture, conversion, and aneurysm-related
death, was not associated with any of the size categories.
One may only speculate why growth was not different in
the size groups. Measurement of diameter in a multicenter
registry is not so standardized as in a single-center study
with a few CT scan readers and uniform imaging technique.
While aneurysm diameter at the minor dimension of the
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largest diameter is part of the EUROSTAR protocol, the
absence of a core laboratory to independently assess diam-
eter measurements may enhance the lack of uniformity. To
enable larger interobserver variation, a relatively large
threshold of 8 mm was used to define the presence of
absence of growth. Nevertheless, data accumulated in a
registry no doubt will lack the accuracy of smaller studies.
Third, and equally important, in many cases smaller degrees
of aneurysm growth, endoleak, or migration may lead to
secondary interventions before the preset threshold of 8
mm diameter increase was reached. In this regard, hard end
points such as rupture and aneurysm-related death may
constitute a better parameter than the more subjective
measurement of diameter.
Proponents of EVAR have been criticized because they
failed to clearly demonstrate any advantage of the tech-
nique with respect to protecting patients from AAA rup-
ture.42 In this respect, it should be noted that the risk for
rupture of small aneurysms (diameter 5.5 cm) after
EVAR in the present study was 0.002 ruptures per patient-
year, which compares favorably with 0.008 in the similar
size category in the trial arm with the initially conservative
management from the UK Small Aneurysm Trial. Rupture
rates per size group were calculated as Number of rup-
tures/(Number of patients in group  mean duration of
follow-up). Reduction of the risk for rupture with EVAR in
medium-sized and large aneurysms as observed in the
present study demonstrated, as expected, even larger differ-
ences. The rupture rate in patients in group B was 0.004,
and should be compared with rates of 0.03 to 0.14, as
derived from the literature in untreated aneurysms of 5 to
5.9 cm.4-6,43 In group C we found a rupture rate of 0.015,
which may be compared with 0.25 per patient-year.4,44
Although these comparisons may not be statistically robust,
it must be considered that with regard to larger aneurysms
a scientifically sound assessment may not likely be per-
formed and comparison of the outcome of different man-
agement strategies must be judged on alternative sources of
information.
Post-EVAR rupture, the ultimate failure of stent-graft
treatment, was observed after use of most of the device
brands reported on in this registry. Analysis of many cases
with post-EVAR rupture reported in the literature have
revealed potentially avoidable causes, such as poor patient
selection, deployment errors, or unrecognized or untreated
endoleaks.45,46 In a previous EUROSTAR publication a
cumulative rupture rate of 1% per year was documented.18
The present 0.7% annual rupture rate at 4 years in the entire
series signifies some improvement, but still differs from
annual cumulative rates of approximately 0.2% found in a
number of institutional series.34,47-49
It was surprising that at our screening of articles on
open AAA repair no studies were found in which the initial
aneurysm diameter was included as a covariate for outcome
analysis. The single exception was a study of the data for
patients with primary surgery enrolled in the UK Small
Aneurysm Trial.12 It is understandable that the aneurysm
diameter in this particular study demonstrated little varia-
tion (5.5 cm), precluding a useful conclusion about a
possible correlation. A comparison of the relation between
aneurysm size and procedural outcome after open AAA
surgery and EVAR at this time is essentially muddled by
two aspects: First, the distribution of small, medium, and
large aneurysms is unknown for almost any published study
on open repair; and second, the respective contribution
from aneurysm-related and unrelated death to the overall
mortality was differentiated in few studies.36,50 For this
reason a size-stratified analysis within the randomized trials
that are under way will be important.
The limitations of this study include the large number
of patients who were lost to follow-up. Data for more than
half of the patients after the 2-year interval were not avail-
able, despite regular reminders to participants in the study.
This aspect, which probably is inherent to a voluntary
registry such as EUROSTAR, may improve with the recent
introduction of electronic data submission via a website.
The proportion of patients with missing follow-up data was
comparable in the three groups. A standard error well
below 10% after 4 years is adequate for a valid assessment.
However, missing data may detract from the accuracy of
the cumulative event rates during follow-up.
Overall, size differences are strongly associated with
adverse outcomes during follow-up. Underlying causes,
such as various types of endoleak, migration, limb kinking,
thrombosis, and aneurysm enlargement, correlated some-
times disparately with aneurysm size groups. However, all
of these variables correlated with either end point, conver-
sion, rupture, or aneurysm-related death, underscoring the
interrelation between one another. The high incidence of
medical risk factors still makes EVAR the preferred man-
agement option in most patients with large aneurysms.
Old-technology stent grafts appeared important to some
extent for adverse outcome, but less so than larger size of
the aneurysm. Careful analysis of the causes of treatment
failure remains indicated to achieve optimal long-term out-
come. Until these interrelationships are better understood,
intensified surveillance of patients receiving endograft
treatment of a large aneurysm after 3 years of follow-up,
when adverse events occur most frequently, appears a rea-
sonable approach. With regard to patients with small aneu-
rysms, the outcome of EVAR appears excellent. This find-
ing may justify reappraisal of currently accepted
management strategies.
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DISCUSSION
Dr Kenneth Ouriel (Cleveland, Ohio). I want to congratu-
late you on a nice analysis of a very large group of patients. I was
intrigued by the very low rate of all-cause death and aneurysm-
related death in the smaller aneurysm group, rates that compete
successfully with the surveillance arm of the UK Small Aneurysm
Trial. In fact, the risks for all-cause mortality was 11% after en-
dografting in your study, versus 18% in the ultrasound surveillance
group in the UK Small Aneurysm Trial. I have one question. Is it
time for a randomized trial of endovascular repair versus surveil-
lance in patients with small aneurysms?
Dr A. G. Peppelenbosch. Admittedly, long-term results of
early death rates and aneurysm-related death rates, and rupture
rates are excellent in small aneurysms. However, we still believe
that, owing to the complication rates in the long term, and that’s
not sure, it should be still that small aneurysms should not be
treated. Regarding your question of whether this should be a
randomized trial, I think it should be. Yes, it is time for such a trial.
Dr Piergiorgio Cao (Perugia, Italy). Ken Ouriel found out
my question. Anyway, I’d like to say another thing. In your very
low aneurysm rate and mortality rate in small aneurysms, you have
48% of patients treated with Vanguard; is that correct? The oldest
patients were treated with Vanguard. Thus many of the aneurysm-
related deaths were related to failure of a graft that is no longer on
the market. Do you have any comment on that? Can you expect
that the results concerning the small aneurysm treated with EVAR
are better than reported in your study, if you extrapolated it out
from Vanguard?
Dr Peppelenbosch. Well, we have done a univariate analysis
of device brands, and we found no correlation with any of the
device brands. However, we also have done this with all brands
combined, and that’s the subject of our next study. And we find
that there is a significant difference between the old brands com-
bined and the newer brands.
Dr Christopher K. Zarins (Stanford, Calif). It seems intu-
itively obvious that patients with large aneurysms may not do quite
so well as patients with small aneurysms. But I should note that
your group sizes—small, medium, and large aneurysms—were not
comparable, particularly in the type of device used in each group.
In our own analysis of more than 1200 patients over 6 years
using a single device, with multivariate and univariate analysis,
there was no relationship between aneurysm size and outcome
measures. So I wonder if you have done Cox proportional hazards
models, including the device and the aneurysm size, not the
aneurysm group size, to determine whether, indeed, aneurysm size
is a significant variable for your outcome results?
Dr Peppelenbosch. We have done that, and aneurysm size is
one of the predictors of this outcome.
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